Lexicon Pharmaceuticals Inc

LXRX

Add to Watchlist

2.230USD

-0.100-4.29%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Lexicon Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

95 / 382

Overall Ranking

215 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Lexicon Pharmaceuticals Inc Highlights

StrengthsRisks

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 4036.46% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 49.80M.

Undervalued

The company’s latest PE is -31.23, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 301.10M shares, increasing 2.34% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 512.43K shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.520

Target Price

+51.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Lexicon Pharmaceuticals Inc is 5.66, ranking 332 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 21.10M, representing a year-over-year increase of 1572.11%, while its net profit experienced a year-over-year increase of 95.88%.

Score

Industry at a Glance

Previous score

5.66

Change

0



Financials

5.91

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.88

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.69

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Lexicon Pharmaceuticals Inc is 5.98, ranking 332 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -31.23, which is -100.00% below the recent high of 0.00 and -9.42% above the recent low of -34.17.

Score

Industry at a Glance

Previous score

5.98

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 95/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Lexicon Pharmaceuticals Inc is 7.60, ranking 281 out of 382 in the Biotechnology & Medical Research industry. The average price target is 1.90, with a high of 6.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.60

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Lexicon Pharmaceuticals Inc is 9.25, ranking 21 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.67 and the support level at 1.66, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.40

Change

-0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Lexicon Pharmaceuticals Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 67.79%, representing a quarter-over-quarter decrease of 1.30%. The largest institutional shareholder is Invesco, holding a total of 512.43K shares, representing 0.12% of shares outstanding, with 59.83% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Artal International S.C.A.

154.73M

+13.62%

Invus Public Equities Advisors, LLC

42.77M

+9.88%

Fidelity Management & Research Company LLC

37.83M

-2.19%

Ulys, L.L.C.

6.99M

+28.22%

Millennium Management LLC

4.82M

+25.87%

BlackRock Institutional Trust Company, N.A.

3.17M

--

Sessa Capital

3.00M

--

Jane Street Capital, L.L.C.

1.72M

+277.70%

Geode Capital Management, L.L.C.

2.50M

+4.26%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lexicon Pharmaceuticals Inc is 3.74, ranking 117 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.05. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Lexicon Pharmaceuticals Inc

LXRX

6.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment